Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Intravenous administration for fluid and electrolyte replacement in patients with deficits of water and electrolytes,Maintenance of fluid and electrolyte balance when oral intake is inadequate,Treatment of hypovolemia (low blood volume) due to various causes such as dehydration, burns, or surgery
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable as a fixed value; infused electrolytes distribute and are eliminated according to individual ion kinetics (e.g., sodium t½ ~30 min, chloride t½ ~1–2 h) with rapid redistribution.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
PLASMA-LYTE 56 is a crystalloid solution; its components are not metabolized. Electrolytes are distributed and eliminated via renal excretion and normal physiological pathways. The solution itself is not subject to hepatic metabolism.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Primarily renal; >90% of infused electrolytes are excreted unchanged in urine; fecal elimination negligible (<5%).
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal (<5%); electrolytes (Na+, Cl-, K+, Mg2+, acetate, gluconate) are not significantly protein-bound.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Approximately 0.2–0.3 L/kg for sodium and chloride, corresponding to extracellular fluid volume; distributed throughout ECF.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
100% by intravenous route; not administered orally (bioavailability not applicable).
Intravenous: 100% bioavailability.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of potassium and magnesium accumulation; use with caution and monitor electrolytes in moderate impairment (GFR 30-59 m L/min).
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific adjustment required; however, monitor electrolytes in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Dose based on weight and clinical status; typical initial infusion rate: 5-10 m L/kg/hour, adjusted based on response and electrolyte monitoring.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution due to reduced renal function; start at lower infusion rates (e.g., 50-100 m L/hour) and monitor for fluid overload and electrolyte disturbances.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
No black box warning is provided for this drug.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload (e.g., congestive heart failure, pulmonary edema),Monitor electrolytes, fluid balance, and renal function during administration,Avoid in patients with hypervolemia, since this may exacerbate fluid overload conditions,Use with caution in patients receiving corticosteroids or corticotropin, as they may increase risk of fluid and electrolyte disturbances,Solutions containing acetate should be used with caution in patients with hepatic insufficiency
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypersensitivity to any component of the solution,Clinically significant hypervolemia (fluid overload),Hyperkalemia (for solutions containing potassium),Severe renal impairment (anuria or oliguria) unless dialysis is performed,Acute or chronic metabolic alkalosis (for solutions containing acetate)
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions; maintain normal diet unless otherwise directed by physician. Avoid excessive potassium-rich foods if renal impairment exists.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Excreted into breast milk in negligible amounts; considered compatible with breastfeeding. M/P ratio not applicable as endogenous electrolytes.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No specific dose adjustments during pregnancy. Use standard dosing based on clinical status; avoid fluid overload in preeclampsia or cardiac conditions.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Plasma-Lyte 56 is a balanced crystalloid solution containing acetate and gluconate as buffers, which may reduce the risk of hyperchloremic metabolic acidosis compared to 0.9% saline. It is isotonic (osmolarity 406 m Osm/L) but hypotonic in plasma due to metabolism of anions, making it suitable for maintenance fluid therapy. Use caution in patients with renal impairment due to potassium content (13 m Eq/L). Not for co-administration with blood products via same tubing due to calcium content (5 m Eq/L).
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This solution provides fluids and electrolytes to maintain hydration and balance.,It contains potassium; follow dietary restrictions if you have kidney problems.,Report any signs of fluid overload (swelling, shortness of breath) or electrolyte imbalances (muscle cramps, weakness, irregular heartbeat).,Do not eat or drink anything unless instructed by your healthcare provider during infusion.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 IN PLASTIC CONTAINER is classified as Category C. No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.